
No Stock Yet
Editas, Beam Win Bullish Views as Cantor Launches Gene Editing Coverage
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Cantor Fitzgerald initiated coverage on Editas Medicine Inc (NASDAQ:EDIT) with an Overweight rating and a price target of $15.The analyst says that following the recent pipeline reprioritization and p
Expert Ratings for Editas Medicine
Analysts have provided the following ratings for Editas Medicine (NASDAQ:EDIT) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings23930Last 30D010001M Ago01
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
UpgradesAccording to Alembic Global, the prior rating for Woodward Inc (NASDAQ:WWD) was changed from Neutral to Overweight. Woodward earned $0.49 in the first quarter, compared to $0.56 in the year-ag
Cantor Fitzgerald Starts Editas Medicine at Overweight With $15 Price Target
08:58 AM EST, 02/01/2023 (MT Newswires) -- Editas Medicine (EDIT) has an average rating of hold and price targets ranging from $7 to $36, according to analysts polled by Capital IQ. Price: 10.15, Chan
Editas Medicine Price Target Announced at $15.00/Share by Cantor Fitzgerald
Editas Medicine Price Target Announced at $15.00/Share by Cantor Fitzgerald
Editas Medicine (NASDAQ:EDIT) Receives New Coverage From Analysts at Cantor Fitzgerald
Stock analysts at Cantor Fitzgerald initiated coverage on shares of Editas Medicine (NASDAQ:EDIT – Get Rating) in a report released on Tuesday, The Fly reports. The brokerage set an "overweight" rati
Editas Medicine Initiated With an Outperform at Cowen
Editas Medicine (EDIT) Crossed Above the 50-Day Moving Average: What That Means for Investors
Why Shares of Editas Medicine Jumped This Week
Loading...
No Stock Yet